Modern drug development has never been more complex. Gene therapies, cell-based treatments, and advanced biologics all demand measurement methods that are sensitive, reproducible, and fully regulatory-ready. For sponsors navigating this landscape, having the right bioanalytical services partner from the start is one of the smartest investments a program can make.
The difference between a well-designed bioanalytical strategy and an afterthought can mean months of timeline delay, failed IND submissions, or costly assay rework. The stakes are simply too high for generic solutions.
What Bioanalytical Services Actually Cover
Bioanalytical services span a broad scientific territory. At their core, they involve developing, validating, and deploying assays that quantify drug levels, immune responses, biomarkers, and safety signals in biological samples. For advanced therapeutics, this scope expands considerably to include molecular quantification of vector genomes, anti-drug antibody detection, viral biodistribution, and immune cell profiling.
Accelevir offers a unified suite of services supporting small molecules, biologics, vaccines, and cell and gene therapy programs. The laboratory's mission centers on partnering with biotech and biopharma innovators to transform complex scientific questions into validated, regulatory-ready data packages.
Assay Development From Discovery Through Phase 3
One of the most important qualities of a strong bioanalytical partner is the ability to support a program across its full arc. Early discovery assays often operate under different technical standards than GLP-compliant clinical testing, yet continuity of methodology matters enormously when comparing data across development phases.
Accelevir supports seamless transitions from non-GLP discovery workflows to clinical-grade testing, including GLP-like practices, custom or platform-based assay development, and validation for PK, PD, TK, ADA, NAb, and biomarker endpoints. This continuity protects scientific integrity and simplifies regulatory submissions.
Tailored Methods for Novel Modalities
Standard assay platforms were not designed with AAV gene therapy or CAR-T cell programs in mind. Novel therapeutic modalities require assays that are purpose-built for the unique behavior of viral vectors and engineered cells in vivo. Assay development must account for low copy numbers, complex biological matrices, PCR inhibitors, and cross-reactive immune responses.
Multiplex dPCR assays for vector genome integrity, ADA and neutralizing antibody testing, and biodistribution analytics are all examples of fit-for-purpose methods tailored specifically to the demands of gene therapy programs.
PBMC Processing Services as the Foundation
Many bioanalytical readouts begin with immune cells. For any endpoint that depends on T-cell function, cytokine production, or immune phenotyping, the quality of PBMC processing services directly determines what the assay can and cannot detect. Integrating high-integrity PBMC isolation with endpoint analytical workflows under one quality system eliminates a major source of inter-laboratory variability.
Integrated processing and analysis workflows support:
- ADA and neutralizing antibody profiling on isolated immune cells
- T-cell proliferation and cytotoxicity assays
- ELISpot and FluoroSpot for antigen-specific immune responses
- Cytokine multiplex using Luminex and ELISA platforms
- Immunophenotyping including Tregs, CD4/CD8 ratios, and memory subsets
Regulatory Readiness Is Built In, Not Added Later
A common and costly mistake in bioanalytical planning is treating regulatory compliance as something that can be layered on at the end of a study. By the time an IND or BLA is approaching, assay validation gaps are expensive to fix and nearly impossible to hide. The smarter approach is building regulatory readiness into every assay from the beginning.
Deep familiarity with FDA S12 guidance, EMA ATMP requirements, and ICH principles means that every data package produced is designed for agency review. The scientific team engages at the study design stage, not just the execution stage, ensuring the bioanalytical strategy is aligned with the regulatory pathway from day one.
Supporting the Full Range of Therapeutic Areas
Proven bioanalytical support spans infectious disease, oncology, gene therapy, and immunology. In infectious disease, this includes HIV, HBV, HDV, influenza, RSV, and emerging pathogen assays, as well as ultrasensitive viral load and reservoir quantification. In oncology and immuno-oncology, immune response profiling, CRS risk monitoring for cell therapies, and tumor antigen-specific immune monitoring are all within scope.
For biologics and vaccine programs, method development includes immunogenicity testing, neutralization assays, and companion diagnostic assay support. Biosimilar and comparator testing, including equivalency studies and assay bridging, rounds out a comprehensive service offering.
Conclusion
Great science requires great measurement. Bioanalytical services are not a commodity. They are a strategic pillar of drug development, and the quality of your data from day one will shape every regulatory decision that follows. Partnering with a CAP/CLIA-certified laboratory that understands the full complexity of modern therapeutic programs ensures your assays are built for the rigor your program demands.